The Journal of Experimental Medicine
ReproCELL
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 27 August 2001. doi:10.1084/jem.194.5.581
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 192K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keller, P.
Right arrow Articles by Bessler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keller, P.
Right arrow Articles by Bessler, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/9/581/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 5, September 3, 2001 581-590


Original Article

FES-Cre Targets Phosphatidylinositol Glycan Class A (PIGA) Inactivation to Hematopoietic Stem Cells in the Bone Marrow

Peter Kellera, Jennifer L. Paynea, Gabi Tremmlb, Peter A. Greerc, Mirella Gabolib, Pier P. Pandolfib, and Monica Besslera
a Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110
b Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
c Cancer Research Laboratories, Departments of Biochemistry and Pathology, Queen's University, Kingston, Ontario K7L 3N6, Canada

Correspondence to: Monica Bessler, Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., Box 8125, St. Louis, MO 63110-1093. Tel:314-362-8807 Fax:314-362-8826 E-mail:mbessler{at}im.wustl.edu.

A somatic mutation in the X-linked phosphatidylinositol glycan class A (PIGA) gene causes the loss of glycosyl phosphatidylinositol (GPI)-linked proteins on blood cells from patients with paroxysmal nocturnal hemoglobinuria. Because all blood cell lineages may be affected it is thought that the mutation occurs in a hematopoietic stem cell. In transgenic mice, germline transmission of an inactive Piga gene is embryonic lethal. To inactivate the murine Piga gene in early hematopoiesis we therefore chose conditional gene inactivation using the Cre/loxP system. We expressed Cre recombinase under the transcription regulatory sequences of the human c-fes gene. FES-Cre inactivated PIGA in hematopoietic cells of mice carrying a floxed Piga allele (LF mice). PIGA- cells were found in all hematopoietic lineages of definitive but not primitive hematopoiesis. Their proportions were low in newborn mice but subsequently increased continuously to produce for the first time mice that have almost exclusively PIGA- blood cells. The loss of GPI-linked proteins occurred mainly in c-kit+CD34+Lin- progenitor cells before the CFU-GEMM stage. Using bone marrow reconstitution experiments with purified PIGA- cells we demonstrate that LF mice have long-term bone marrow repopulating cells that lack GPI-linked proteins, indicating that recombination of the floxed Piga allele occurs in the hematopoietic stem cell.

Key Words: hematopoiesis, stem cell, c-fes, paroxysmal nocturnal hemoglobinuria, conditional gene inactivation


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS